WO2002007737A1 - Metodo para el tratamiento del glaucoma y la hipertension ocular mediante la administracion de nucleotidos - Google Patents
Metodo para el tratamiento del glaucoma y la hipertension ocular mediante la administracion de nucleotidos Download PDFInfo
- Publication number
- WO2002007737A1 WO2002007737A1 PCT/ES2001/000271 ES0100271W WO0207737A1 WO 2002007737 A1 WO2002007737 A1 WO 2002007737A1 ES 0100271 W ES0100271 W ES 0100271W WO 0207737 A1 WO0207737 A1 WO 0207737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- administration
- effective amount
- ocular
- glaucoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention is associated with the treatment of glaucoma and ocular hypertension.
- the invention relates to the use of certain substituted L-methylene and D-imido compounds of ATP for the treatment of glaucoma and hypertension.
- the method for the treatment of glaucoma and ocular hypertension falls within the field of pharmacology.
- Glaucoma is a condition that causes progressive damage to the optic nerve, and, finally, a total loss of vision.
- the causes of this condition have been the subject of numerous studies for many years, but it is not yet fully understood.
- the main symptom or risk factor for this condition is high intraocular pressure (hypertension), due to an excess of aqueous humor in the anterior chamber of the eye.
- aqueous humor accumulates in the anterior segment of the eye are not fully understood, but an elevated intraocular pressure (PI ⁇ ) can be partially controlled by the administration of substances that act by reducing the production of aqueous humor, such as beta- carbonic anhydrase blockers and inhibitors, or by increasing the drainage of aqueous humor by means of parasympathomimetics.
- substances that act by reducing the production of aqueous humor such as beta- carbonic anhydrase blockers and inhibitors
- parasympathomimetics One of the main problems of the use of drugs for the treatment of glaucoma are its serious side effects. Parasympathomimetics such as pilocarpine produce blurred vision and other visual side effects, which can lead to both the patient decreasing compliance with the treatment and the cessation of therapy.
- Carbonic anhydrase inhibitors can, on the other hand, cause serious side effects, such as nausea, indigestion, fatigue, and metabolic acidosis, which can affect treatment compliance and / or the need to withdraw treatment.
- beta-blockers have been increasingly associated with serious pulmonary side effects attributable to their effects on beta-2 lung tissue receptors.
- Sympathomimetics cause tachycardias, arrhythmia and hypertension. There is therefore a continuing need for therapies that control the elevated intraocular pressure associated with glaucoma.
- Nucleotides are naturally occurring substances, recently investigated for their possible efficacy as intraocular pressure reducers.
- the chemically modified adenine nucleotides of interest in the present invention are commercially available compounds that exhibit similar mechanisms of PI ⁇ decrease to those described for D- ⁇ , ⁇ -methylene ATP and D- ⁇ , ⁇ -methylene
- ATP derivatives and dinucleotides have been shown to decrease PI ⁇ (Peral, A., Hoyle, CHV, Pelaez, T. and Pintor, Invest. Ophtalmol. Vis. Sci. Vol. 41 (4) , B714 (2000)).
- PI ⁇ Peral, A., Hoyle, CHV, Pelaez, T. and Pintor, Invest. Ophtalmol. Vis. Sci. Vol. 41 (4) , B714 (2000).
- the method object of the present invention relates to pharmaceutical compositions and their use in the treatment of glaucoma and ocular hypertension.
- the present invention provides certain classes of adenine nucleotides with functional agonist activity of the P2X receptor, and methods of their use in the treatment of glaucoma and ocular hypertension.
- the L- ⁇ , ⁇ -methylene ATP, D- ⁇ , ⁇ -imidoATP, Ap and derivatives of the present invention are functionally defined by their ability to bind to P2X purinergic cell receptors and evoke responses similar to that of ATP, the natural agonist , when you join these receptors.
- ATP agonists any agent that binds to P2X receptors and produces a cellular action in a manner very similar to ATP, decreasing the PI ⁇ .
- ATP agonists any agent that binds to P2X receptors and produces a cellular action in a manner very similar to ATP, decreasing the PI ⁇ .
- Various assays are used for the determination of ATP agonists, some of which are explained below.
- the PI ⁇ was measured twice before the application of any of the three compounds, 30 min. and just before the instillation of any of them.
- the "ATP agonists” were dissolved in saline (0.9% NaCl) and applied topically to the eyes. The measurements were taken every 30 min during the first hour and then every hour until the PI ⁇ returned to its initial value.
- An experimental protocol similar to the previous one has been described in Pintor, J., Peral, A., Navas, B., Pelaez, T. and Gallar, Invest.Ophtalmol.Vis.Sci. Vol. 41 (4), B715 (2000).
- the "ATP agonists" can be prepared and administered through various vehicles and methods of administration.
- “ATP agonists” can be prepared as liquid drops, liquid washes, gels, ointments, sprays and liposomes.
- its administration can be done topically, by catheter-pump systems, selective or delayed release devices, spray, nebulizers, orally, by injection or suppositories.
- the data obtained have been statistically analyzed, and showed significant differences using a t studen t test. We have considered as significant differences those values where p ⁇ 0.005 compared to the control value.
- the results presented in the figures correspond to the mean ⁇ sem (standard error of the mean) of eight experiments performed independently, for each of the "ATP agonists".
- ATP analogs of the present invention are found in the definition of agonists of the preceding ATP, and follow the following formulas:
- compositions referred to herein are preferably administered topically and are generally prepared in concentrations of 10 ⁇ g / ⁇ L.
- the resulting solution is applied topically by placing a drop in each eye once or twice a day.
- ATP agonists may be applied through other types of preparations such as liquid drops, liquid washes, gels, ointments, sprays and liposomes. Likewise, they can be administered by catheter-pump systems, selective or delayed release devices, spray, nebulizers, orally, by injection or suppositories. Any of the different forms of administration described will be carried out in such a way that a therapeutically effective amount of the Compounds contact the eye tissues through systemic absorption and circulation.
- Figure 1 - Graph showing the effect of L- ⁇ , ⁇ -MeATP against time, where the decrease in intraocular pressure can be observed, as described in example 1.
- Figure 2. - Graph showing the effect of D- ⁇ , ⁇ -ImidoATP against time, where the decrease in intraocular pressure can be observed, as described in example 2.
- the sample of "ATP agonists" of the present invention was prepared by dissolving 100 ⁇ g of the L- ⁇ compound, ⁇ -MeATP, in 10 ⁇ L of saline (0.9% NaCl). The intraocular pressure is measured twice before instilling any of the compounds (10 ⁇ L), to proceed to measure the PI ⁇ every half hour during the hour after the instillation of the substance, and subsequently every hour until the return of the PI ⁇ to initial values.
- Preferred formulations of the ATP agonists of the present invention include the following:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001270642A AU2001270642A1 (en) | 2000-07-06 | 2001-07-06 | Method for the treatment of glaucoma and ocular hypertension by administering nucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200001670 | 2000-07-06 | ||
ES200001670A ES2173027B2 (es) | 2000-07-06 | 2000-07-06 | Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002007737A1 true WO2002007737A1 (es) | 2002-01-31 |
WO2002007737B1 WO2002007737B1 (es) | 2002-07-18 |
Family
ID=8494145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2001/000271 WO2002007737A1 (es) | 2000-07-06 | 2001-07-06 | Metodo para el tratamiento del glaucoma y la hipertension ocular mediante la administracion de nucleotidos |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001270642A1 (es) |
ES (1) | ES2173027B2 (es) |
WO (1) | WO2002007737A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2385788A (en) * | 2002-01-18 | 2003-09-03 | Inspire Pharmaceuticals Inc | Purinergic receptor ligands for use in reducing intraocular pressure |
WO2011077435A1 (en) * | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869468A (en) * | 1994-04-04 | 1999-02-09 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
WO2000012098A1 (fr) * | 1998-09-01 | 2000-03-09 | Yamasa Corporation | Compositions medicinales pour le traitement des maladies oculaires |
-
2000
- 2000-07-06 ES ES200001670A patent/ES2173027B2/es not_active Expired - Fee Related
-
2001
- 2001-07-06 WO PCT/ES2001/000271 patent/WO2002007737A1/es active Application Filing
- 2001-07-06 AU AU2001270642A patent/AU2001270642A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869468A (en) * | 1994-04-04 | 1999-02-09 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
WO2000012098A1 (fr) * | 1998-09-01 | 2000-03-09 | Yamasa Corporation | Compositions medicinales pour le traitement des maladies oculaires |
Non-Patent Citations (2)
Title |
---|
GHIARDI G.J. ET AL.: "The purine nucleoside adenosine in retinal ischemia-reperfusion injury", VISION RESEARCH, vol. 39, 1999, pages 2519 - 2535 * |
PINTOR J. ET AL.: "Effect of ATP and adeline nucleotides on intraocular pressure in New Zealand rabbits", INVEST. OPHTHALMOL. VIS. SCI., vol. 41, no. 4, 15 March 2000 (2000-03-15), pages B715 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2385788A (en) * | 2002-01-18 | 2003-09-03 | Inspire Pharmaceuticals Inc | Purinergic receptor ligands for use in reducing intraocular pressure |
WO2011077435A1 (en) * | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
Also Published As
Publication number | Publication date |
---|---|
WO2002007737B1 (es) | 2002-07-18 |
AU2001270642A1 (en) | 2002-02-05 |
ES2173027B2 (es) | 2005-12-16 |
ES2173027R (es) | 2002-10-16 |
ES2173027A2 (es) | 2002-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2244209C (en) | Improved concentrated injection and infusion solutions for intravenous administration | |
EP0234854B1 (en) | Use of phosphodiesterase inhibitors and cyclic nucleotide analogues for the manufacture of a medicament for stimulating tear secretion | |
US7018985B1 (en) | Composition and method for inhibiting platelet aggregation | |
Beatty et al. | Elevation of intraocular pressure by calcium channel blockers | |
Impagnatiello et al. | Intraocular pressure–lowering activity of NCX 470, a novel nitric oxide–donating bimatoprost in preclinical models | |
BR112013005438B1 (pt) | Agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo | |
KR20090094090A (ko) | 치료를 위한 방법 및 조성물 | |
ES2259727T3 (es) | Agente oftalmico que contiene heparina. | |
JP2824863B2 (ja) | α▲下1▼―ブロッカー点眼剤 | |
Chu et al. | Active transport of ascorbate across the isolated rabbit ciliary epithelium. | |
EP1118329A1 (en) | Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides | |
AU2001259775B2 (en) | Method for treating retinal degeneration with purinergic receptor agonists | |
KR20120115344A (ko) | 안압을 감소시키는 혼합물, 키트 및 방법 | |
JP2016147918A (ja) | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 | |
Seida et al. | Effect of aminophylline on postischemic edema and brain damage in cats. | |
US4734438A (en) | Norepinephrine potentiated compositions and method of use | |
JP2004505922A (ja) | 抗炎症薬 | |
WO2002007737A1 (es) | Metodo para el tratamiento del glaucoma y la hipertension ocular mediante la administracion de nucleotidos | |
BAR-ILAN et al. | Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151 | |
EP0275249B1 (en) | Continuous intravenous infusion of adenosine to human patients, a unit dosage form of adenosine and use of adenosine for the manufacture of medicaments | |
Gristwood et al. | Studies on the cardiac actions of flosequinan in vitro. | |
Kashiwagi et al. | Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits | |
JPH0717863A (ja) | プラノプロフェン点眼液 | |
JP2003516962A (ja) | 視神経損傷および網膜損傷の処置のためのアデノシンキナーゼのインヒビター | |
Hopwood et al. | An antiadrenergic effect of adenosine on guinea-pig but not rabbit ventricles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
122 | Ep: pct application non-entry in european phase | ||
ENP | Entry into the national phase |
Ref document number: 2002135622 Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: JP |